NEJM Impact Factor 2026: 78.5 | The Pinnacle of Clinical Publishing

NEJM's impact factor is 78.5 in 2024: the highest of any clinical journal, and well ahead of Lancet (88.5), BMJ (42.7), and JAMA (55.0). Around 35,000 manuscripts are submitted annually. About 2,000 get published. The editorial filter is precise: papers that can't answer the question "what should physicians do differently after reading this?" rarely survive triage, regardless of how strong the science is.

What is NEJM's impact factor?

NEJM's current impact factor is 78.5 for the 2024 reporting year. The metric is useful, but the decision should be based on trend direction, acceptance dynamics, editorial behavior, and how your manuscript profile matches what editors actually advance.

Year-by-year impact factor trend (2017-2024)

Source: Clarivate Journal Citation Reports (JCR), 2025 edition.

Why the IF spiked and where it's settled

The 2021 spike to 78.5 was driven entirely by COVID papers accumulating citations at a pace no normal publishing year can sustain. The landing at 78.5 is the real post-pandemic baseline, and the stability from 2023 to 2024 confirms it. Only The Lancet (88.5) and JAMA (55.0) are in the same tier : JAMA sits at 55.0, BMJ at 42.7, Lancet at 88.5.

At this IF level, the number mostly signals journal tier for external audiences. The actual publication decision for researchers comes down to whether the paper meets the practice-changing clinical evidence bar, not the specific IF value.

What NEJM editors are looking for

NEJM is not a general outlet for good medical science. It wants studies that can alter practice, guidelines, or risk stratification at scale. Large randomized trials, definitive multicenter cohorts, and mechanistic findings with immediate patient consequence fit. Purely preclinical work doesn't, unless patient relevance is explicit and near term.

NEJM editors apply one test: will publishing this paper change how physicians treat patients in the next 12-24 months? Large RCTs, landmark cohort studies with definitive endpoints, and mechanistic findings with direct therapeutic implications pass. Purely preclinical work, basic science without clinical correlation, and observational studies that don't shift practice don't, regardless of technical quality.

Here is the surprising operational detail most authors miss, NEJM often synchronizes same day online publication with major conference presentations, so editorial timing can be influenced by external meeting calendars, not only peer review speed. This is why two manuscripts with similar technical quality can have very different outcomes at editorial triage.

What the 5% acceptance rate actually means

At roughly 5% acceptance, your manuscript must clear two bars: clinical consequence and confidence in execution. Editors ask whether a practicing clinician could change behavior based on your findings. If the answer is uncertain, rejection follows quickly. This explains why many technically strong studies never leave triage.

With roughly 35,000 annual submissions and about 2,000 published articles, the math is stark. The desk rejection filter removes around 95% of submissions, meaning exceptional papers with the wrong framing : strong data, weak clinical consequence : are rejected as fast as weak papers. The clinical consequence question is the actual filter, not data quality alone.

Timeline: submission to decision

Initial editorial calls often come within 48-72 hours. If a week passes with no decision, the manuscript is likely in serious consideration. Full peer review, if the paper advances, typically adds 4-8 weeks. NEJM is also known for coordinating publication with major conference presentations (ACC, ASCO, ASH, AHA) : if your paper aligns with an upcoming meeting, mentioning it in the cover letter can influence timing discussions.

Have a clear fallback plan if NEJM declines. JAMA, Lancet, and JAMA Internal Medicine are the natural next targets depending on disease area, and a fast resubmission matters if you're in a competitive space.

What gets desk rejected at NEJM

With 95% of submissions rejected before peer review, NEJM's desk rejection criteria are worth understanding precisely.

Common desk rejection triggers at NEJM:

• No clear practice-changing implication. The single most common reason for desk rejection is a paper where editors can't write one sentence that answers: "After this is published, physicians should do X differently." Basic science, even exceptional basic science, is rejected if the clinical chain is not explicit.
• Underpowered trials or observational studies with weak causal claims. NEJM has high standards for trial design. Small RCTs, underpowered subgroup analyses, and observational studies making causal claims are regularly rejected.
• Scope mismatch. Papers better suited for specialty journals (cardiology-specific findings with no general medicine relevance, for example) are redirected quickly.
• Previous publication as a preprint with limited novelty remaining. NEJM is selective about preprints : they prefer submissions that haven't been widely distributed or cited before peer review completes.
• Non-US-centric research without global relevance framing. While NEJM publishes international research, papers from non-US settings that don't establish global applicability of findings face harder triage.

How NEJM compares to JAMA and BMJ

NEJM vs JAMA vs Lancet is the primary decision for clinical researchers. A useful heuristic: NEJM for practice-changing US trials and mechanistic findings with immediate clinical application; JAMA for research with health system or policy implications; Lancet for global health and European research, and for papers with policy-level public health consequences. The journals overlap substantially, but each has editorial leanings that increase acceptance odds for the right framing.

Open access options and costs

NEJM is a subscription-based journal with no standard gold open access option for research articles. Authors can't pay to make their original research article immediately open access in NEJM itself.

For authors who need open access compliance (common under NIH, Wellcome Trust, or UKRI mandates), NEJM research articles are deposited in PubMed Central after a 6-month embargo period. This satisfies most major funder open access requirements without an APC.

NEJM Evidence is the newer companion journal (launched 2022) with a focus on clinical evidence synthesis. It offers immediate open access with an APC of approximately $3,900. For authors who need immediate OA or are publishing evidence reviews, NEJM Evidence is worth evaluating as a primary target alongside NEJM itself.

There are no page charges or color figure fees at NEJM.

When to submit to NEJM

Submit to NEJM only when your primary endpoint is practice changing on day one. If your study is strong but not yet guideline shaping, send it to a top specialty clinical journal first and protect calendar time. This is not a journal to test incomplete narratives. Submit when the manuscript is already in target shape, not when you hope reviewer feedback will create the shape for you.

If you are aiming at this tier and want to reduce desk rejection risk, run a pre-submission diagnostic first: try the quick diagnostic.

FAQ

What is the NEJM impact factor in 2024?

NEJM impact factor is 78.5 in 2024, matching its 2023 level after COVID era normalization.

How hard is it to get published in NEJM?

It's extremely hard. Acceptance is around 5%, and about 95% of submissions do not reach external peer review.

What kind of research does NEJM publish?

NEJM prioritizes large clinical trials, major cohort analyses, and findings with direct patient care consequences.

How long does NEJM take to review?

Initial editorial decisions can come in 48-72 hours. If sent to full review, first decisions often take 4-8 weeks.

Why did the NEJM impact factor spike in 2021?

COVID citation intensity drove an exceptional short term spike in citations, then the metric settled as citation patterns normalized.

Sources and further reading

Impact factor data sourced from Clarivate Journal Citation Reports (released June 2025). For submission guidelines, see the NEJM author center.

For full submission requirements, acceptance rate data, and desk rejection patterns, see the NEJM journal guide. For submission strategy and how to avoid desk rejection, see our guide on avoiding desk rejection.

The Bottom Line

NEJM's IF of 78.5 places it among the top clinical medicine journals. That number comes from landmark clinical trial results that get cited thousands of times. It doesn't mean your paper can't belong there , it means the bar is clinical practice-changing evidence, not just well-executed research. Know where your manuscript stands before you aim for the top.

See also

• NEJM acceptance rate
• NEJM submission guide
• Lancet vs NEJM
• Lancet impact factor